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Acinar-to-Ductal Metaplasia (ADM) is considered the main
origin of pancreatic pre-neoplastic lesions that eventually
develop into Pancreatic Ductal Adenocarcinoma (PDA).
ADM could be a decisive step during tumorigenesis,
selecting plastic cells for a more aggressive subsequent
tumorigenesis. Our results indicate that TGFb, a cytokine
overexpressed during early and late pancreatic tumorigen-
esis, is an inducer of ADM and set up a favorable context for
the emergence of oncogene-driven neoplastic lesions. This
questions the usual dichotomist vision of TGFb in PDA.BACKGROUND & AIMS: Transforming growth factor beta
(TGFb) acts either as a tumor suppressor or as an oncogene,
depending on the cellular context and time of activation.
TGFb activates the canonical SMAD pathway through
its interaction with the serine/threonine kinase type I and II
heterotetrameric receptors. Previous studies investigating
TGFb-mediated signaling in the pancreas relied
either on loss-of-function approaches or on ligand over-
expression, and its effects on acinar cells have so far
remained elusive.
METHODS: We developed a transgenic mouse model allowing
tamoxifen-inducible and Cre-mediated conditional activation of
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pancreatic acinar compartment.
RESULTS:We observed that TbRICA expression induced acinar-
to-ductal metaplasia (ADM) reprogramming, eventually facili-
tating the onset of KRASG12D-induced pre-cancerous pancreatic
intraepithelial neoplasia. This phenotype was characterized by
the cellular activation of apoptosis and dedifferentiation, two
hallmarks of ADM, whereas at the molecular level, we evi-
denced a modulation in the expression of transcription factors
such as Hnf1b, Sox9, and Hes1.
CONCLUSIONS: We demonstrate that TGFb pathway activation
plays a crucial role in pancreatic tumor initiation through its
capacity to induce ADM, providing a favorable environment for
KRASG12D-dependent carcinogenesis. Such ﬁndings are highly
relevant for the development of early detection markers and of
potentially novel treatments for pancreatic cancer patients.
(Cell Mol Gastroenterol Hepatol 2017;4:263–282; http://
dx.doi.org/10.1016/j.jcmgh.2017.05.005)
Keywords: Pancreas; Cancer; TGFb; Acinar-to-Ductal
Metaplasia; KRASG12D.
n mammals, the pancreas is a bifunctional organ.1 TheaAuthors share co-ﬁrst authorship.
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accounts for more than 90% of the organ’s mass. Acinar cells
secrete digestive enzymes that are further collected in a
network of ducts that discharge pancreatic juices into the
duodenum. The endocrine tissue, represented by islets of
Langerhans embedded in the exocrine pancreas, controls
blood glucose levels by secreting hormones such as insulin
and glucagon. Embryonically, all pancreatic lineages arise
from amultipotent progenitor present at day E9 in themouse
endoderm.2 The fate of the pancreas is dictated by the
expression of progenitor markers such as SOX9 and CK19 for
ductal cells, MIST1, PTF1A, CPA1, and ELA1 for acinar cells,
and NGN3 for endocrine cells.2–4 Note that PTF1A is required
for the speciﬁcation of the pancreatic multipotent progenitor
cells and is later expressed only in the adult acinar
compartment.5
The adult pancreas is highly plastic6 to ensure organ
integrity in response to internal (intracellular activation of
digestive enzymes, obstruction of main ducts potentially as
a result of gallstones) or external stresses (alcohol, trauma).
Repair and regeneration of the injured organ are orches-
trated by many cell types including acinar cells, centroacinar
cells, ductal cells, immune cells, and stellate cells.7,8 The
existence of a resident stem cell population in the organ
remains controversial.9,10 Many studies1,11,12 have focused
on post-injury pancreatic regeneration and demonstrated
the crucial role of acinar cells during this process. Indeed,
under severe stress conditions such as pancreatitis, acinar
cells undergo acinar-to-ductal metaplasia (ADM), a
morphologic and transcriptional conversion into duct-like
cells with embryonic progenitor cell properties.5,7,13 These
metaplastic cells are then capable of proliferating to
replenish the damaged organ. In the case of a sustained
stress signal or concomitant oncogenic activation such asKRAS activating mutations (eg, KRASG12D), the metaplastic
cells cannot revert to a differentiated state, as generally
observed in the case of an acute stress. This pancreatic
erosion process constitutes a favorable setting for the onset
of low-grade pancreatic intraepithelial neoplasia (PanIN).14
Progression toward PanINs of higher grade and eventually
pancreatic ductal adenocarcinoma (PDA) is associated with
recurrent mutations or genetic/epigenetic alterations in
tumor suppressor genes (INK4/ARF, TP53).15,16 Impor-
tantly, SMAD4/DPC4, a core component of the transforming
growth factor beta (TGFb) signaling pathway, is deleted in
50% of PDAs.16–18 Members of the TGFb superfamily of
transforming growth factors are involved in embryonic
development, regulation of homeostasis, and the pathogen-
esis of a variety of diseases.19,20 TGFb signaling occurs
through a heterotetrameric receptor complex composed of 2
subunits, the type I and type II TGFb receptors (TbRI and
TbRII, respectively). On binding to its receptors, TGFb en-
ables TbRII to transphosphorylate TbRI, which in turn ac-
tivates the canonical SMAD pathway (phosphorylation of
SMAD2 and SMAD3 that further interact with SMAD4 to
accumulate inside the nucleus) and other signaling path-
ways (MAPK, RHOA, and PI3K/AKT).21 In cancer, TGFb
behaves as either a tumor suppressor or a tumor promoter.
Indeed, TGFb is generally considered to be a tumor sup-
pressor early in tumor development (tumor initiation) by
restricting epithelial cell growth (through cytostasis and
apoptosis).19,22,23 However, in later stages of tumorigenesis
(tumor progression), TGFb has oncogenic properties
through its capacity to regulate cellular plasticity by stim-
ulating biological processes, including extracellular matrix
deposition, immune evasion, epithelial-to-mesenchymal
transition (EMT), and stemness.22,24–27
Unlike the majority of previously published studies in
which the TGFb signaling pathway was abrogated, our
present work addresses the consequences of TGFb cell-
autonomous activation in the pancreatic epithelial lineage.
To this end, we generated a unique mouse model enabling
us to express a constitutively activated TbRI receptor
(TbRICA) exclusively in pancreatic acinar cells, starting
either in the embryo or after birth. Hence, we demonstrate
that the speciﬁc activation of TGFb signaling in pancreatic
acinar cells induced ADM reprogramming and eventually
facilitated the onset of KRASG12D-induced PanINs and PDA
progression.
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Mouse Strains and Handling
The LSL-TbRICA strain was previously generated in the
laboratory of Dr Bartholin28,29 (TbRICA is tagged with the
hemagglutinin epitope at the C-terminus). We and others
have functionally validated the TbRICA transgene after suc-
cessful in vivo targeting in different subcellular compart-
ments or organs such as immune cells,28,30–35 ovaries,36 and
uterine tissue.37 In the present study, we only used TbRICA
males to circumvent the mosaic phenotype occurring in fe-
males as a result of random X chromosome inactivation and
associated inactivation of the transgene in a proportion of
cells, as previously reported for other transgenes located on
the X chromosome.38 LSL-KrasG12D,39 Pdx1-Cre,40
Ptf1a-CreERT2,5 and Rosa-CreERT241 alleles have been
described previously. E2A-Cre42 allele has been described
previously; [E2A-Creþ/þ] or [E2A-Creþ/-] mice were crossed
with [LSL-TbRICA] (R) mice.
E19.5 embryos were removed from [LSL-TbRICA] females
(R) previously impregnated by [Pdx1-Cre] males (C). To this
end, pregnant females (R; n ¼ 11) were euthanized at 19.5
days post coitum, and embryos were collected (n ¼ 92).
Five-week-old mice bearing the Ptf1a-CreERT2 allele along
with LSL-TbRICA and/or LSL-KrasG12D transgenes were
injected with tamoxifen (Sigma-Aldrich #T5648; St Louis,
MO; 3 mg per injection) to induce recombination of the LSL-
TbRICA and LSL-KrasG12D alleles. Animals from the 3-day
cohort received 2 injections (day 1 and day 3) and were
killed at day 4. Animals from the 3-week, 2-month, and
6-month cohorts received 5 injections (days 1, 3, 5, 7, and 9)
and were killed 3 weeks, 2 months, and 6 months after the
ﬁrst injection, respectively. For Rosa26-CreERT2 mice,
tamoxifen was injected 7-10 weeks after birth.
Mice were housed and bred in the AniCan speciﬁc
pathogen-free animal facility of the Centre de Recherche en
Cancérologie de Lyon, France. The experiments were per-
formed in compliance with the animal welfare guidelines of
the European Union and with French legislation (CECCAPP
protocol #CLB-2014-008).Histology and Immunohistochemistry/
Immunoﬂuorescence
Histologic (H&E staining) and immunohistochemical
experiments were performed as described previously.43,44
For immunohistochemistry experiments, the primary anti-
bodies used were anti-CK19 (Developmental Studies Hy-
bridoma Bank, Iowa City, IA) and anti-INSULIN (Dako
A0564; Glostrup, Denmark). The secondary antibodies used
were rat immunoglobulin G (HþL) biotinylated (Vector
#BA-9400; Vector Laboratories, Burlingame, CA) and guinea
pig immunoglobulin G (HþL) biotinylated (Vector
#BA-7000). For AMYLASE/CK19 double immunoﬂuores-
cence, primary antibodies were anti-AMYLASE (Sigma-
Aldrich A8273) and anti-CK19 (Developmental Studies Hy-
bridoma Bank) and secondary antibodies used were Rabbit
IgG (HþL) Alexa Fluor 647-conjugated (Life Technologies
#A-21245 GAR647) and Rat IgG (HþL) Alexa Fluor594-conjugated (Life Technologies #A-21209 DAR594). For
AMYLASE/SOX9 double immunoﬂuorescence, primary an-
tibodies were anti-AMYLASE (Santa-Cruz #166349), anti-
SOX9 (Millipore #AB5535) and secondary antibodies used
were Rabbit IgG (HþL) Alexa Fluor 647-conjugated (Life
Technologies #A-21245 GAR647) and Mouse IgG (HþL)
Alexa Fluor 488-conjugated (Life Technologies #A-11001
GAM488), but artiﬁcial colors (red for AMYLASE and green
for SOX9) were given with the Zeiss software to be consis-
tent with AMYLASE/CK19 double staining. Nuclei were
counterstained with DAPI, and images were acquired with a
Zeiss Imager M2 AX10 (Carl Zeiss AG, Oberkochen,
Germany).Quantiﬁcation of Pancreatic Lesions
Histologic scoring of pancreatic lesions was performed
by using 1 representative H&E tissue slide per animal
(3–8 animals per condition). Pancreatic lesions were
scored from PanIN1 to PanIN3/PDA and were counted.
The area of the analyzed tissue was determined by
using ImageJ software (National Institutes of Health,
Bethesda, MD), and lesion counts were normalized to this
area.RNAscope
TbRICA mRNA and Smad7 mRNA were detected in situ by
using the RNAscope technology (Advanced Cell Diagnostics,
Newark, CA) for the Hu-TbRI (catalog no. 431041) and
Mm-Smad7 (catalog no. 429411) probes, respectively.Cell Culture
The rat pancreatic acinar cell line AR42J (ATCC) was
cultured in Dulbecco modiﬁed Eagle medium supple-
mented with fetal calf serum (Lonza Group, Basel,
Switzerland) and penicillin/streptomycin (Gibco Labora-
tories, Gaithersburg, MD). AR42J cells were infected with
murine retroviral particles containing a wild-type (pZip-
Neo) vector or a KRASG12D-expressing vector (pZIP-Neo-
KRASG12D; donated by Dr J. Caramel, CRCL, Lyon, France)
and further cultured in the presence of Geneticin (PAA
Laboratories, Linz, Austria). TGFb was used at the ﬁnal
concentration of 10 ng/mL.
For proliferation assays, AR42J-WT and AR42J–
KRASG12D were seeded in triplicate at 100,000 cells per
well onto 12-well plates and treated with TGFb (10 ng/
mL; PeproTech #100-21; Rocky Hill, NJ) for 24 and 48
hours. For each time point, cells were morphologically
examined by phase-contrast microscopy and counted by
using the trypan blue exclusion method. Kinase inhibitors
were used as follows: 5 mmol/L TbRI inhibitor (SB
431542, Sigma-Aldrich #S4317), 10 mmol/L MEK inhibitor
(U0126 monoethanolate, Sigma-Aldrich #U120), 2.5 mmol/
L JNK inhibitor (Selleckchem #S4901; Houston, TX), 2.5
mmol/L PI3K inhibitor (LY294002, Selleckchem #S1105),
and 2.5 mmol/L p38 inhibitor (SB 203580; Enzo Life Sci-
ences, Farmingdale, NY; #BML-EI286-0001). Inhibitors
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maintained during the 48 hours of TGFb treatment.Ela1: Forward: 50-TGGTCCTGTATGGACACAGT-30
Reverse: 50-CCGTCATTCTGACTCAGGTT-30
Mist1: Forward: 50- TGGCTAAAGCGACGTGTCC-30
Reverse: 50- CTTCCGACTGGGGATCCGA-30
Cpa1: Forward: 5 0- ACTTTGTGGGACACCAGGTT-30
Reverse: 50- ACATCAATGGGGATACCGGC-30
Sox9: Forward: 50- GTGCTGAAGGGCTACGACTGGA-30
Reverse: 50- GTTGTGCAGATGCGGGTACTGG-30
Hnf1b: Forward: 50- TCCCATCTGCAATGGTGGTC-30
Reverse: 50- GCTGTGCACAAAGTGAGTGG-30
Hes1: Forward: 50- GTCCCCGGTGGCTGCTAC-30
Reverse: 50- AACACGCTCGGGTCTGTGCT-30Immunoprecipitation
For protein analysis, mouse pancreas tissue was lysed
and homogenized in RIPA buffer (50 mmol/L Tris-HCl
pH 7.4, 150 mmol/L NaCl, 1 mmol/L ethylenediamine tet-
raacetic acid, 0.5% sodium deoxycholate, 0.1% sodium
dodecylsulfate, and 1% Nonidet) containing a cocktail of
protease and phosphatase inhibitors. After protein quanti-
ﬁcation, 40 mg protein was used for loading controls, and 2.5
mg protein was used for the immunoprecipitation assay by
using the SMAD2/3 antibody (Cell Signaling Technology
#3102; Danvers, MA) and protein G Agarose Fast Flow
(EMD Millipore). Proteins were separated by sodium
dodecylsulfate–polyacrylamide gel electrophoresis and
detected by Western blot analysis.Serpine-1: Forward: 50- CCCACGGAGATGGTTATAG -30
Reverse: 50- ATCACTTGCCCATGAAGAG -30
TbRICA: Forward: 50- TTGTGAACAGAAGTTAAGGC -30
Reverse: 50- AGCATAATCAGGAACATCAT -30
Actb: Forward: 50- GCAGGAGTACGATGAGTCCG-30
Reverse: 50- ACGCAGCTCAGTAACAGTCC-30
Bmf: Forward: 50- AGGTACAGATCGCCAGAAAGC-30
Reverse: 50- CTCGGTTCTGCTGGTGTTGTTG-30Western Blot Analysis
Western blotting was performed as previously
described.29 The primary antibodies used were anti-
phospho-SMAD2 (Cell Signaling #3101), anti-SMAD2 (Invi-
trogen #51-1300; Carlsbad, CA), anti-SMAD2/3 (Cell
Signaling #3102), anti-SMAD4 (Epitomics #1676-1; Burlin-
game, CA), anti-RAS (Santa Cruz Biotechnology), anti-b-actin
(Sigma-Aldrich #A5441 Clone AC15), and anti-b-tubulin
(mouse monoclonal; Sigma-Aldrich). Peroxidase-labeled
anti-rabbit and anti-mouse secondary antibodies were
purchased from Dako (mouse immunoglobulin G horse-
radish peroxidase–conjugated DAKO P0260, rabbit immu-
noglobulin G horseradish peroxidase–conjugated DAKO
#P0448).Polymerase Chain Reaction and Reverse
Transcription Quantitative Polymerase Chain
Reaction
PCR to detect the recombined TbRICA allele was per-
formed as described previously.28
AR42J-WT and AR42J-KRASG12D were treated for 48
hours with 10 ng/mL TGFb (PreproTech #100-21) before
being washed with phosphate-buffered saline (PBS). RNA
extraction was performed by using the RNeasy mini kit
(QIAGEN #74104; Hilden, Germany), according to the
manufacturer’s instructions.
For pancreatic tissues, RNA extraction from frozen tis-
sue was performed by using guanidine thiocyanate
enriched lysis solution containing 5 mol/L guanidine
thiocyanate (Sigma-Aldrich #G6639), 2.5 mmol/L sodium
citrate, 0.5% N-lauryl sarcosine (Sigma-Aldrich #61739),
and 1% b-mercaptoethanol. Lysates were centrifuged at
14,000 rpm at 4C for 5 minutes to eliminate cell frag-
ments. RNA was consecutively puriﬁed with the RNeasy
mini kit (QIAGEN #74104), according to the manufac-
turer’s instructions.
After RT (ThermoFisher Scientiﬁc, Waltham, MA) by
using random primers, qPCR was performed by using the
MESA GREEN qPCR MasterMix Plus for SYBR Assay ROX(Eurogentec, Liège, Belgium; #RT-SY2X-06þWOU) and the
following primers:RAS Activity Assay
GTP-bound RAS (activated RAS) was measured in cell
lysates incubated with beads coated with RAF1-RBD (Up-
state; EMD Millipore). The experiment was performed by
using the active RAS detection kit (Cell Signaling Technology
#8821).Cell Death Assays
For the caspase-3 activity assay, AR42J-WT and AR42J-
KRASG12D cells were treated with 10 ng/mL TGFb for 12
hours. Caspase-3 activity was determined by using the
CASPASE-3/CPP32 Fluorimetric Assay Kit, according to the
manufacturer’s instructions (Gentaur Biovision, Kampenh-
out, Belgium). For the annexin V assay, AR42J-WT and
AR42J-KRASG12D cells were seeded in duplicate and treated
with 10 ng/mL TGFb for 48 hours (PeproTech). Cells were
harvested in PBS and incubated with annexin V–ﬂuorescein
isothiocyanate and propidium iodide (BD Pharmingen, San
Diego, CA), according to the manufacturer’s instructions,
and analyzed by ﬂow cytometry (FACS Calibur cytometer;
BD Biosciences). For the TUNEL cell death assay, AR42J-WT
and AR42J-KRASG12D (24 hours of TGFb treatment) cells or
tissue sections were ﬁxed in formaldehyde before being
permeabilized with PBS-0.2% Triton X-100 and incubated in
TdT buffer, 1 mmol/L CoCl2 (Sigma-Aldrich # 15862-1 mL-F)
for 5 minutes. Then they were incubated with TdT buffer
(30 mmol/L Tris, 150 mmol/L sodium cacodylate, pH7.5), 1
mmol/L CoCl2, Biotin16-dUTP (Sigma-Aldrich
#11093070910), TdT enzyme (Roche #11767305001;
Basel, Switzerland) for 1 hour at 37C. The reaction was
September 2017 TGFb-signaling Activation in Pancreas 267stopped by incubating the samples with 300 mmol/L NaCl,
2.5 mmol/L sodium citrate for 15 minutes. After washing
with PBS, unspeciﬁc sites were saturated with 2% bovine
serum albumin, 10 mmol/L PBS. After washing with PBS,
slides were incubated with streptavidin-Cy3 (Jackson
ImmunoResearch, West Grove, PA) diluted 1/200 in 2%
bovine serum albumin in PBS. Finally, the nuclei were
counterstained with DAPI (Sigma-Aldrich), and images were
acquired with a Zeiss Imager M2 AX10.
Results
Transforming Growth Factor Beta-induced Cell
Growth Inhibition In Vitro Is Enhanced in Acinar
Cells Expressing KRASG12D
We initially explored the combined effects of KRAS acti-
vation and TGFb treatment on rat AR42J pancreatic acinar
cells45,46 infected either with a wild-type retroviral vector
(AR42J-WT cells) or with a KRASG12D retroviral vector
(AR42J-KRASG12D cells). We ascertained that KRASG12D was
present and functional in AR42J-KRASG12D cells via Western
blot analysis, which revealed a signiﬁcant increase in the level
of active GTP-bound RAS protein compared with AR42J-WT
cells (Figure 1A). Examination of the cells by phase-contrast
microscopy revealed that AR42J-KRASG12D cells treated
with TGFb grew to a lower cell density than the other cell
populations (Figure 1B). This growth-inhibition effect was
conﬁrmed by counting cells, highlighting a clear decrease in
the number of AR42J-KRASG12D cells treated with TGFb
(Figure 1C). Furthermore, this decrease was much stronger
than that observed for AR42J-WTcells. Functionally, although
these latter cellswere poorly responsive to TGFbwith respect
to their capacity to phosphorylate SMAD2 (P-SMAD2), AR42J-
KRASG12D cells displayed a drastic increase in P-SMAD2 on
TGFb treatment, as evidenced by Western blot analysis
(Figure 1D). As expected, the levels of SMAD2/3 and SMAD4
were affected neither by KRAS activation nor by TGFb
treatment. Taken together, these results demonstrate that the
activation of KRAS potentiates TGFb cell growth inhibition
and SMAD pathway activation in rat pancreatic acinar cells.KRASG12D Sensitizes Acinar Cells to
Transforming Growth Factor Beta–induced
Apoptosis and Dedifferentiation In Vitro
Next, we speculated that the inhibition of AR42J-KRASG12D
pancreatic acinar cell growth in the presence of TGFbwas due
to apoptosis.47 Microscopic examinations revealed that TGFb-
treated AR42J-KRASG12D cells were characterized by the pres-
ence of poorly refringent cells (Figure 1B, inset) and by an
increase in the number of ﬂoating cells (data not shown),
evoking the presence of apoptotic cells. The highest rates of
apoptosis were observed in AR42J-KRASG12D cells treated with
TGFb, as demonstrated by caspase-3 activity (Figure 2A), ter-
minal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) (Figure 2B), and annexin-V (Figure 2C) assays. TGFb-
induced apoptosis mainly occurs via the mitochondrial
pathway by downregulating antiapoptotic factors of the BCL-2
family (BCL-xL) and by positively regulating proapoptoticfactors of the BCL-2 family.23 Proapoptotic Bmf (BCL2-
modifying factor) was previously shown to be upregulated af-
ter TGFb treatment in the normal murine mammary epithelial
cell line NMuMG.48 Reverse transcription quantitative poly-
merase chain reaction (RT-qPCR) experiments performed on
total RNA prepared from AR42J-WT and AR42J-KRASG12D cells
showed an increase of Bmf mRNA expression after TGFb
treatment (Figure 2D). This activation is compromised in the
presence of SB431542, an inhibitor of TbRI kinase activity.
These observations are consistent with the increase in
apoptosis observed by caspase-3, TUNEL, and annexin-V
assays.
Phase-contrast micrographs revealed that TGFb-treated
AR42J-KRASG12D cells (and to a lesser extent AR42J-WT cells)
acquired a spindle-like shape after TGFb treatment
(Figure 3A). RT-qPCR did not reveal signiﬁcant changes in
response to TGFb in EMT markers such as Snai1, Zeb1,
Vimentin, and Cdh2 in AR42J-WT and AR42J- KRASG12D cells
(data not shown). In contrast, a decrease in the expression of
acinar markers (Ela1, Cpa1, andMist1) and a marked increase
in the expression of ductal/dedifferentiation/progenitor
markers (Hes1, Hnf1b, Sox9) were observed in AR42J-
KRASG12D cells treated with TGFb (Figure 3B).
These morphologic and transcriptional changes are reminis-
cent of ADM. Among the genes we tested and known to be
positively correlated toADM,we focusedour interest onHnf1b
because it was the best TGFb responder in experiments
presented in Figure 3B. TGFb signaling ismediated by both the
canonical SMADpathwayandnon-canonical pathways (MAPK,
PI3K, RHO-RAC).22,23 AR42J-WT cells were cultured in
the presence of TGFb along with kinase inhibitors of
both the canonical and non-canonical TGFb pathways.
RT-qPCR revealed thatHnf1b activationdepends onSMADand
MEK pathways but not on JNK, P38, or PI3K pathways
(Figure 3C).
These results demonstrate that TGFb treatment and
KRAS activation cooperate to compromise AR42J rat acinar
cell differentiation by increasing both apoptosis and ductal-
like reprogramming, two hallmarks of ADM in vivo.Activation of Transforming Growth Factor Beta
Signaling in the Mouse Embryonic Pancreas
Severely Compromises the Development of the
Acinar Compartment
We then analyzed whether the activation of TGFb
signaling (alone or in combination with KRAS activation)
could compromise the homeostasis of pancreatic acinar
cells in vivo. To achieve this, we used a mouse strain ([LSL-
TbRICA] also called R) containing a constitutively active
TGFb type I receptor (TbRI), previously generated in the
laboratory of Dr Bartholin by using a knock-in strat-
egy.28,30 Transgene expression under the control of the
ubiquitous CAG (human cytomegalovirus enhancer and
chicken b-actin) promoter is repressed by a ﬂoxed tran-
scriptional Stop (LSL, Lox-Stop-Lox), which can be excised
in the presence of Cre recombinase. E2A-Cre allows
recombination early during embryonic development
before the E5 uterine wall implantation stage. We never
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Figure 1. KRASG12D po-
tentiates TGFb-mediated
cell growth inhibition of
AR42J rat pancreatic
acinar cells. (A) Immuno-
blot of RAS-GTP and total
RAS on AR42J-WT and
AR42J-KRASG12D protein
extracts. (B) Phase micro-
scopy of AR42J-WT and
AR42J-KRASG12D cells 48
hours after TGFb treat-
ment. Insets represent
higher magniﬁcations
ﬁelds. Scale bar,
50 mm/L. NT, untreated.
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count of AR42J-WT and
AR42J-KRASG12D cells at
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treatment. Representative
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(D) Immunoblot of SMAD
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suggesting that the expression of TbRICA at an early stage
of development was embryonically or prenatally lethal. To
restrict TGFb gain-of-function to the whole organism of
mice postpartum, we generated [Rosa-CreERT2; LSL-TbRICA]
mice that were subsequently treated with tamoxifen to
induce ubiquitous Cre-mediated recombination, the Rosa-
26 locus being active in all adult lineages (Figure 5A). All
[Rosa-CreERT2; LSL-TbRICA] mice (n ¼ 4) injected with
tamoxifen at the age of 7–10 weeks were euthanized 4 or 5
days after treatment because of the rapid onset of a highlydetrimental phenotype, whereas all of the wild-type mice
survived (n ¼ 5) (Figure 5B). Histologic examination of
the internal organs revealed that the pancreas was the
most impaired organ, with many apoptotic ﬁgures
(Figure 5C), clearly indicating a deleterious effect of TbRI
activation in the pancreas, which could explain the severe
phenotype of these animals. To test this hypothesis, we
expressed TbRICA in all of the pancreatic epithelial line-
ages by crossing [LSL-TbRICA] (R) and [Pdx1-Cre] (C)
mice,40 which drives Cre recombinase expression in em-
bryonic progenitors (at E8.5) of all pancreatic epithelial
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TGFb cooperate to activate
apoptosis of AR42J rat
acinar cells. (A) Caspase-3
assay after 12-hour TGFb
treatment. (B) TUNEL assay
after 24-hour TGFb treat-
ment. Upper panel, ﬂuores-
cence microscopy. Lower
panel, graphs showing per-
centage of TUNEL-positive
cells under ﬂuorescence mi-
croscopy and counted in
each condition (>1000 cells).
(C) Annexin-V/propidium io-
dide (PI) assay after 48-hour
TGFb treatment. Upper
panel, raw FACS data. Upper
right box drawn on each plot
corresponds to apoptotic cell
population (cells positive for
both annexin-V and PI).
Lower panel, quantiﬁcation of
apoptotic cells in upper right
boxes drawn on plots above.
For (A–C), representative
experiment performed in trip-
licate (means ± standard
deviation) is shown. (D)
RT-qPCR of proapoptotic
Bmf (BCL2-modifying factor)
marker. Cells were treated (or
not) with TGFb ± TbRI inhibi-
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For each condition, mRNA
level is represented as mean
± standard deviation of 1
representative experiment
performed in triplicate.
September 2017 TGFb-signaling Activation in Pancreas 269lineages (Figure 5D). Histologic analysis revealed that
[Pdx1-Cre; LSL-TbRICA] embryos (CR) presented pancreatic
defects characterized by a massive reduction in the
number of mature acinar cells (hematoxylin-eosin stain-
ing) along with abnormally abundant ductal structures
(shown by CK19 expression) (Figure 5E). No obviousdefect in the endocrine compartment was observed (using
INSULIN staining as a marker) (Figure 5E). These latter
results show that pancreatic activation of TGFb signaling
at an early stage of development affects normal pancre-
atic development by impacting the acinar cell
compartment.
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Cells After Birth Results in SMAD Pathway
Activation
To circumvent the afore-mentioned embryonic develop-
mental defects, we investigated the effects of TbRICA expression
starting after birth. To that end, we used the tamoxifen-
inducible Pft1a-CreERT2 mouse allele (CER),5 which limits the
expression of Cre recombinase to adult acinar cells (Figure 6A).
Micewere injectedwith tamoxifenat 5weeks of age. Excision of
the ﬂoxed transcriptional Stop in the pancreas of CERR(þTAM)
mice was validated by PCR on genomic DNA (Figure 6B).RT-qPCR experiments revealed a signiﬁcant enrichment in
TbRICA mRNA in CERR(þTAM) pancreata compared with R
pancreata,whichwas correlatedwithupregulationof theTGFb-
target gene Serpine-1 (Figure 6C). Immunoprecipitation assays
and Western blot analyses revealed a marked accumulation of
P-SMAD2 in the pancreata of CERR(þTAM) compared with
wild-type mice (Figure 6D) (as expected the level of total
SMAD2 in the lysates or in the immunoprecipitates did not
differ between wild-type and CERR(þTAM) mice). Next, we
ascertained that the expression of the TbRICA transgene was
restricted to the pancreatic acinar compartment by performing
Genotype
# litters # pups # pups/litter WT [E2a-Cre] [LSL-TβRICA] [E2a-Cre; LSL-TβRICA]
[E2a-Cre+/+] x [LSL-TβRICA] 4 18 4.5 18 0
[E2a-Cre+/-] x [LSL-TβRICA] 5 29 5.8 10 7 12 0
Fisher's exact 
test ns ns ns *
Figure 4. Early activation of TbRICA during mouse development is embryonically lethal. [E2A-Creþ/þ] or [E2A-Creþ/-] mice
were crossedwith [LSL-TbRICA] (R) mice. Total number of litters, pups, and offspring genotype distribution are presented. Fisher’s
exact test was performed to statistically conﬁrm absence of [E2A-Creþ/-; LSL-TbRICA] mice. Nonsigniﬁcant (ns),P> .05; *P< .05.
September 2017 TGFb-signaling Activation in Pancreas 271RNAscope (Figure 6E). It is worth noting that 100% of the
acinar cells expressed the transgene, and that transgene
expression was not observed in other lineages (ducts and is-
lets). In addition, the detection of Smad7 mRNA by RNAscope
suggested that the canonical TGFb-SMAD pathway was acti-
vated in vivo in the presence of TbRICA. These results clearly
indicate that the conditional TbRICA transgene is restricted to
pancreatic epithelial cells on tamoxifen treatment and is
correlated with the activation of the SMAD pathway in vivo.Acinar-to-Ductal Metaplasia in Response to
TbRICA Expression
Activating mutations of KRAS (eg, KRASG12D) are found in
>90% of human PDAs and are sufﬁcient to trigger carcino-
genesis when targeted in mice.49 We generated mice
expressing TbRICA (R) and KrasG12D (K) transgenes either
alone or in combination under the control of Pft1a-CreERT2
(CER), and we performed histologic analyses of pancreata
collected at different time points after tamoxifen injection
(3 days, 3 weeks, 2 months, and 6 months). As early as 3 days
after tamoxifen treatment (Figure 7A), CERR(þTAM) and
CERKR(þTAM) pancreata presented a severe reduction in the
acinar compartment associated with increased apoptosis
(Figure 7B; H&E, black arrowheads; TUNEL). CERK(þTAM)
were normal and CERKR(þTAM) undistinguishable from
CERR(þTAM) pancreata. Amylase is a marker of acinar cells,
whereas CK19 and SOX9 are ductal markers. SOX9 is also an
early positive regulator of ADM. Interestingly, we observed
that CERR(þTAM) and CERKR(þTAM) pancreata displayed
double-positive CK19þ/amylaseþ or SOX9þ/amylaseþ acinar
cells (Figure 7B, immunoﬂuorescence, white arrowheads), a
feature of acinar cells undergoing early ADM reprogramming
to form ductal-like structures.50 These “ducts” consisted of
simple cuboidal epithelial cells andwere characterized by the
expression of stemness markers and ductal markers. These
double-positive acinar cells (CK19þ/amylaseþ, SOX9þ/
amylaseþ) most likely correspond to a regenerative process
accompanying acinar cell loss. Three weeks after tamoxifen
treatment (Figure 8), CERK(þTAM) pancreata were still
normal. However, compared with the analysis performed 3
days after tamoxifen injection, we observed a drastic loss in
the acinar compartment (amylaseþ), concomitantly with a
large increase in the number of duct-like structures (CK19þ),
when TbRICA was expressed (CERR(þTAM)), independently
of oncogenic KRAS activation (eg, KRASG12D).Tumorigenesis Induced by KRASG12D Is
Enhanced by TbRICA
Two and 6 months after tamoxifen treatment (Figure 9A
andB), we observed in CERR(þTAM) pancreata amassive loss
of acinar tissue replaced by adipose tissue, a phenomenon
known as acinar fatty inﬁltration (AFI). In CERK(þTAM)
pancreata, PanINs and ADM lesions were clearly distin-
guishable without clear evidence of AFI. Interestingly,
CERKR(þTAM) double mutant pancreata presented both AFI
and PanINs. Precise quantitative and qualitative analysis of
epithelial lesions (Figure 9C) revealed at 2 months a 3-fold
increase in the number of PanIN1 in CERKR(þTAM)
compared with CERK(þTAM) and the absence of PanIN2 in
CERK(þTAM), whereas these lesions were detectable in
CERKR(þTAM). At 6 months the analysis showed the pres-
ence of PanIN3/PDA only in CERKR(þTAM) (absence in
CERK(þTAM)), with three-fourths of CERKR(þTAM) mice
developing PDA compared with 0 of 5 CERK(þTAM) mice
(Fisher’s exact test, P ¼ .0476; data not shown).
In double mutants, a strong desmoplastic reaction asso-
ciatedwith a drastic reduction of the acinar compartment was
observed at 2 and 6 months. Immunohistochemistry analysis
of pancreata at 2 months and 6 months after tamoxifen in-
duction conﬁrmed the ductal nature of the lesions and
demonstrated that TbRICA expression in CERR(þTAM) mice
does not further affect endocrine islets compared with
CERK(þTAM), which we have previously shown to present
disorganized islets architecture51 (Figure 10).
Our results demonstrate that in adult mice (1) activation
of TGFb signaling induces ADM by disrupting acinar cell
homeostasis, leading to a drastic increase in the number of
ductal structures at the expense of acinar structures; and
(2) activation of TGFb signaling in combination with onco-
genic KRAS activation leads to the early onset of
pre-neoplastic lesions that can naturally evolve toward
high-grade/locally invasive lesions.
Discussion
Tumorigenesis can be divided into 3 consecutive steps.
The priming stage corresponds to biological processes (such
as cellular stress, inﬂammation, dedifferentiation) that pre-
dispose normal cells to further transformation by creating a
propitious cellular state or microenvironment. The initiation
stage is represented by all genetic and epigenetic events
sufﬁcient for the acquisition of the transformed phenotype
Figure 5. Expression of
TbRICA in mouse embryo
compromises develop-
ment of acinar compart-
ment. (A) Breeding
strategy to target TbRICA
expression in whole adult
body by using tamoxifen-
inducible Rosa26-CreERT2
allele. (B) Overall survival
(Kaplan-Meier analysis) of
wild-type (WT) and
[Rosa26-CreERT2; LSL-
TbRICA] mice after tamox-
ifen injection. Log-rank
(Mantel-Cox) test. **P ¼
.0047. (C) Histology of
pancreata prepared from
WT and [Rosa26-CreERT2;
LSL-TbRICA] mice 5 days
after tamoxifen injection.
White arrows, apoptotic
cells. Scale bars, 200 mm.
(D) Breeding strategy to
target TbRICA expression in
all epithelial pancreatic lin-
eages from embryonic day
8.5 (E8.5) by using Pdx1-
Cre allele. (E) Histology of
pancreata prepared from
WT and [Pdx1-Cre; LSL-
TbRICA] (CR) E19.5 em-
bryos. Scale bars, 200 mm.
mag, magniﬁcation; TAM,
tamoxifen.
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metastatic stage is characterized by mechanisms conferring
aggressiveness and invasive properties to cancer cells (such
as inactivation of TP53 or SMAD4 tumor suppressors).
Bioactive TGFb, which is found in normal and pathologic
pancreas tissues, plays a crucial role in both normal tissue
homeostasis and pancreatic diseases. The TGFb paradox in
cancer consists in the observation that TGFb behaves either
as a tumor suppressor or as a tumor promoter depending
on the cellular context, especially in the 3 above-described
stages. The studies conducted so far to address the multi-
faceted role of TGFb in pancreatic cancer in vivo mostly
relied on loss-of-function approaches (receptor inactivation,SMAD inactivation) and ligand gain-of-function (effect is not
restricted to cancer cells). These strategies did not provide a
clear answer as to the precise role of TGFb signaling in
pancreatic epithelial cells. In the present study, we devel-
oped a conditional and inducible TGFb gain-of-function
mouse model expressing a constitutively active type I
TGFb receptor (TbRICA) in the pancreas. We demonstrated
that cell-autonomous expression of TbRICA in the epithelial
pancreatic compartment could severely compromise acinar
cell homeostasis by inducing early ADM reprogramming.
This phenotype was associated with the activation of both a
proapoptotic program and a ductal-like differentiation
program. Lately, the predominant role of necroptosis (a
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Figure 6. Inducible
TbRICA expression in
pancreatic acinar cells
after birth results in
SMAD pathway activa-
tion in vivo. (A) Breeding
strategy to express TbRICA
after birth in pancreatic
acinar cells by using
tamoxifen-inducible Pft1a-
CreERT2 allele. Black ar-
rows represent genotyping
primers. Sizes of expected
fragments are shown. (B)
PCR on genomic DNA to
assess excision of STOP
signal in CERR pancreas
after tamoxifen injection.
(C) RT-qPCR of TbRICA
and Serpine-1 on total
RNA from pancreata pre-
pared from mice treated
with tamoxifen. Expres-
sion level in R mice was
arbitrarily set at 1 (mean ±
standard deviation; 2 in-
dependent experiments).
(D) Immunoprecipitation of
SMAD2/3 and Western
blot analysis of P-SMAD2
(phospho-SMAD2) and to-
tal SMAD2. Total lysate
was assessed for b-tubulin
and SMAD2. (E) RNA-
scope detection of TbRICA
and Smad7 mRNA on
pancreatic sections from
WT and CERR mice. Scale
bars, 100 mm. (A–E): WT,
wild-type; R, [LSL-TbRICA];
CERR, [Pft1a-CreERT2;
LSL-TbRICA]. mag, magni-
ﬁcation; TAM, tamoxifen.
September 2017 TGFb-signaling Activation in Pancreas 273programmed form of necrosis death) in acinar cell death
was reported in severe experimental mouse pancreatitis.52
We also demonstrated that in the presence of mutated
KRASG12D, TGFb-induced ADM reprogramming facilitates
the onset of PanINs. This work represents a demonstration
that the activation of cell-autonomous TGFb signaling
compromises pancreatic acinar cell identity and eventually
potentiates KRASG12D-driven tumor initiation.Cell-autonomous Transforming Growth Factor
Beta Activation Induces Acinar-to-Ductal
Metaplasia Reprogramming
Three days after TbRICA induction in adult mouse
pancreatic acinar cells, we observed a drastic reduction inacinar tissue as attested by decreased amylase expression in
the pancreata of mice expressing the transgene. This
observation corroborates previous studies, which reported
a repressive role for TGFb on the fate of acinar cells. Indeed,
it was demonstrated that TGFb could inhibit the formation
of acinar tissue ex vivo in cultures of pancreatic embryonic
buds.53 In vivo, by using a transgenic mouse model
expressing a type II TGFb dominant-negative mutant re-
ceptor under the regulation of the metallothionein 1 (Mt1)
promoter, TGFb was shown to be essential for the mainte-
nance of the acinar compartment homeostasis.54 In the
present study, we observed that targeted activation of TGFb
signaling in acinar cells in vivo efﬁciently compromised
acinar identity. At the microscopic level, we observed that
the loss of acinar tissue was associated with massive
Figure 7. TbRICA expression in acinar cells induces apoptosis and ductal-like differentiation 3 days after induction. (A)
Diagram of experimental design for 5-week-old mice injected with tamoxifen and euthanized 3 days later. (B) H&E staining,
TUNEL assay, and immunoﬂuorescence of amylase, CK19, and SOX9. Black arrowheads, apoptotic cells; white arrowheads,
CK19/amylase and SOX9/amylase double-positive cells; WT, wild-type; [Pft1a-CreERT-; LSL-TbRICA], CERR; [Pft1a-CreERT2;
LSL-KrasG12D], CERK; [Pft1a-CreERT2; LSL-TbRICA; LSL-KrasG12D], CERKR. TAM, tamoxifen. Scale bars, 50 mm.
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Figure 8. TbRICA expression in acinar cells leads to regenerative ADM 3 weeks after induction. (A) Diagram
of experimental design for 5-week-old mice injected with tamoxifen and euthanized 3 weeks later. (B) H&E
staining and immunoﬂuorescence of amylase and CK19. WT, wild-type; [Pft1a-CreERT-; LSL-TbRICA], CERR;
[Pft1a-CreERT2; LSL-KrasG12D], CERK; [Pft1a-CreERT2; LSL-TbRICA; LSL-KrasG12D], CERKR. TAM, tamoxifen. Scale bars,
100 mm.
September 2017 TGFb-signaling Activation in Pancreas 275apoptosis and with the appearance of new highly abundant
ductal structures of small diameter. This phenotype is
reminiscent of ADM, a process involved in pancreas
replenishment after tissue injury.1,6,11 During this process
and as observed in the model presented here, the acinar
cells are reprogrammed into a ductal-like cell population,displaying features of progenitor cells, with the ability to
regenerate the different lineages in the injured pancreas.
Recently, Liu et al55 have shown that TGFb could convert
primary human acinar cells to ductal-like cells in vitro,
which corroborates our current in vivo demonstration that
TGFb induces ADM. Although the signals triggering ADM
276 Chuvin et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 2
Figure 10. KRASG12D and
TGFb activation coop-
erate to accelerate
pancreatic tumorigenesis
without affecting endo-
crine compartment.
Immunohistochemical
detection of CK19 and
INSULIN in mice of indi-
cated genotypes 2 and 6
months after tamoxifen in-
duction. [Pft1a-CreERT2;
LSL-TbRICA] (CERR); [Pft1a-
CreERT2; LSL-KrasG12D]
(CERK); [Pft1a-CreERT2;
LSL-TbRICA; LSL-KrasG12D]
(CERKR). Scale bars, 200
mm.
September 2017 TGFb-signaling Activation in Pancreas 277in vivo are poorly known, we demonstrate herein that TGFb
signaling activation is one of these signals.Acinar-to-Ductal Metaplasia Reprogramming
Induced by Transforming Growth Factor Beta
Activation Facilitates KRASG12D-mediated
Carcinogenesis
ADM has largely been documented to represent the ﬁrst
step in pancreatic tumor development by providing a suit-
able surrounding for the malignant transformation of cells
in response to oncogene-driven mutations such as
KRASG12D.12 Here we report a signiﬁcant increase in both the
number and the grade of PanIN lesions in the pancreas of
mice expressing both TbRICA and KrasG12D transgenes in
comparison with age-matched KRASG12D mice. PanINs were
never observed in the presence of TbRICA alone. This
observation supports the idea that KRASG12D generates a
persistent ADM (known as for acinar-to-ductal reprogram-
ming56), facilitating the subsequent onset of PanINs. Active
TGFb thus appears to be crucial to potentiate KRASG12D
transforming properties through its capacity to confer a
ductal-like phenotype to acinar cells that possess progenitor
properties and that are more sensitive to transformation. ItFigure 9. (See previous page). TbRICA expression in acinar c
months after induction. (A) Diagram of experimental design
euthanized 2 or 6 months later. (B) H&E staining. WT, wild-ty
KrasG12D], CERK; [Pft1a-CreERT2; LSL-TbRICA; LSL-KrasG12D], C
epithelial lesions at different grades and observed in CERK and C
TAM, tamoxifen.is worth underlining that the phenotype we observed in the
pancreas of TbRICA mice resembles that of pancreatitis, a
pathology predisposing to PDA.57 In aging mice we observed
that ADM was resolved by AFI, which represents the normal
evolution of chronic pancreatitis when the inﬂammatory
stress ceases. Pancreatitis characterized by ADM has also
been reported to be tightly dependent on TGFb activation.
Indeed, it was shown by others that inhibition of TGFb in
different mouse models, by using a dominant-negative type
II TGFb receptor,58–60 by overexpressing the inhibitory
SMAD7,61 or by using halofuginone to inhibit TGFb-induced
collagen deposition,62 could compromise cerulein-induced
pancreatitis. Pancreatitis has also been shown to be
reversible in the absence of activated KRAS and irreversible
in the presence of activated KRAS,63 demonstrating that
KRASG12D is able to harness the pancreatitis phenotype to
facilitate the development of PanINs. The presence of acti-
vated KRAS would then prevent spontaneous resorption of
the phenotype, driving cells toward persistent ADM and
PanINs. Our ﬁndings, together with these previous studies,
demonstrate that TGFb activation in the pancreas induces
ADM, providing a propitious environment, with features
reminiscent of pancreatitis, for the onset of KRASG12D-
induced PanINs. Hence, cell-autonomous activation of TGFbells accelerates KRASG12D-induced tumorigenesis several
representing 5-week-old mice injected with tamoxifen and
pe; [Pft1a-CreERT-; LSL-TbRICA], CERR; [Pft1a-CreERT2; LSL-
ERKR. Scale bars, 100 mm. (C) Quantiﬁcation of pancreatic
ERKR pancreata 2 months and 6 months after TAM injection.
278 Chuvin et al Cellular and Molecular Gastroenterology and Hepatology Vol. 4, No. 2signaling in pancreatic acinar cells may represent a crucial
step in pancreatitis, which is also known to predispose to
PDA, thus providing a physiopathologic relevance for the
results described in the present study.Simultaneous Transforming Growth Factor Beta
Signaling and KRAS Activation Cooperate to
Induce Apoptosis and Ductal Reprogramming of
Acinar Cells
We demonstrated in vitro and in vivo that the simulta-
neous activation of TGFb and KRAS could cooperate to induce
apoptosis and ductal reprogramming of acinar cells, two
cellular events classically observed in pancreatic ADM.7
Importantly, in the tamoxifen-inducible model, 100% of
pancreatic epithelial cells expressed the TbRICA transgene
in vivo, thus indicating that the deleterious phenotype
observed in the presence of the KRASG12D transgene resulted
from a cell-autonomous functional interaction. Although our
observations indicate that TGFb activation induces direct
ADM reprogramming, the mechanisms dictating cell fate, ie,
apoptotic death versus survival associated with the acquisi-
tion of an ADM phenotype, remain to be uncovered. Indeed,
the mechanisms that allow a proportion of acinar cells to
escape apoptosis and pursue their route toward ADM remain
to be identiﬁed. As suggested by a recent study, the fate of
pancreatic cancer cells is tightly controlled by factors
downstream of TGFb (SNAIL and SOX4).64 David et al64
showed that TGFb-induced EMT resulted in apoptosis acti-
vation and tumor suppressive activity. Hence, in the trans-
formed pancreas, TGFb-induced apoptosis reduces the
number of cancer cells, thus substantiating its tumor sup-
pressive effect at this stage, whereas in the normal pancreas
(the present work), TGFb induced apoptosis and promotes
ADM, thereby proving its oncogenic effect. Whether this
model proposed by David et al can be transposed to un-
transformed cells to study tumor initiation needs to be tested.
On the basis of the use of AR42J rat acinar cells stably
expressing KRASG12D and treated with TGFb, we were able
to show that KRAS activation sensitized acinar cells to both
TGFb-induced apoptosis and dedifferentiation. At the mo-
lecular level, we evidenced in this model a cooperative effect
of both pathways to modulate the expression of Hnf1b, Sox9,
and Hes1. The combination of these 3 transcription factors is
a hallmark of the formation of progenitor cells during
development,3 which is in accordance with the well-
documented role of TGFb as a promoter of stemness.65,66
Indeed, SOX9 and HNF1b are the ﬁrst transcription factors
that commit endoderm cells to pancreatic progenitors dur-
ing organogenesis.5 They are markers of the ductal tree, re-
expressed during ADM.3,14 Moreover, the adult SOX9 has
been shown to be a master positive regulator of the ADM
process.56 Indeed, the ectopic expression of SOX9 in acinar
cells activates the expression of ductal markers and in-
creases KRASG12D-induced ADM, and conversely, inactiva-
tion of Sox9 in KRASG12D-expressing adult acinar cells
compromises the onset of PanINs, conﬁrming its critical role
in the transition toward a ductal phenotype.56 In the present
study, we reported that the in vivo co-expression of TbRICAand KRASG12D was able to induce the onset of amylase/
SOX9 double-positive cells. This feature is known to be
associated with the regenerative process after acinar cell
loss, stemming from double-positive cells for acinar and
ductal markers. The precise role of SOX9 in this model re-
mains to be explored and whether Hes1 and Hnf1b are
direct transcriptional targets of SMAD proteins. How
KRASG12D potentiates their activation is currently under
investigation in our laboratory.Physiopathologic Relevance and Therapeutic
Implications
Our observation that TGFb behaves as a tumor promoter
may seem paradoxical in light of other studies showing that
inactivation of TGFb signaling by inactivating Smad4 or
TbRII accelerates the progression of KRASG12D-induced
lesions.67–72 This is most likely a consequence of both the
gain-of-function approach we used and the stage at which
TGFb signaling was impaired. Indeed, in our model through
its capacity to induce ADM, activation of TGFb signaling
resulted in an increased KRASG12D-induced tumor initiation.
This can be explained by the effect of TGFb on the priming
stage of tumor progression by committing acinar cells to an
ADM differentiation program favorable to transformation. In
contrast, TbRII or Smad4 homozygous deletions facilitate
the progression of KRASG12D-induced preexisting PanINs.
This observation is consistent with the loss of SMAD4 at late
stages and widespread metastatic human diseases.73,74
Furthermore, we recently demonstrated that the activation
of TGFb signaling was sufﬁcient to induce the onset of
ovarian tumors, strongly supporting our current ﬁndings
that this signaling pathway plays an active role in promoting
tumor initiation.36 Overall, this work sheds new light on
another level of complexity for the dual role of TGFb as a
tumor promoter and suppressor.
TGFb or components of its signaling pathway are being
extensively evaluated as a potential therapeutic target, as
attested by the compelling preclinical and encouraging
clinical studies.75 As a consequence of its dual role in cancer,
deciphering TGFb-related functional processes is a prereq-
uisite to develop efﬁcient anti-TGFb therapies. Under-
standing the ﬁrst steps of pancreatic tumorigenesis is
necessary to determine how pancreatic tumor cells acquire
plasticity. Such an effort may provide new therapeutic
strategies aimed at restoring a normal differentiated state.
An example of a successful differentiation therapy was
observed in acute promyelocytic leukemia,76,77 character-
ized by the accumulation of incompletely differentiated
leukemic cells, which could be forced to fully differentiate
on treatment with all-transretinoic acid. More recently,
Fitamant et al78 provided proof-of-concept for differentia-
tion therapy in solid tumors by deleting Yap1 in hepato-
cellular carcinoma, which present features of progenitor
cells. In this context, unveiling the speciﬁc effects of TGFb at
different stages of tumorigenesis may lead to innovative
therapeutic strategies aimed at restoring acinar differenti-
ation and, therefore, at decreasing the deleterious onset of
cellular plasticity. Deﬁning the molecular mechanisms
Figure 11. Schematic diagram showing effect of TGFb signaling activation (alone or in combination with KRASG12D) on
pancreatic acinar compartment. A few days after tamoxifen induction, TbRICA induces acinar cell apoptosis and subsequent
regenerative metaplasia (ADM). In aging mice, ADM is overcome and replaced by AFI. KRASG12D activation alone induces
ADM and PanINs several months after induction. When TbRICA and KRASG12D are simultaneously induced, PanINs develop
much earlier. In the context of TbRICA-induced ADM, KRASG12D induces regenerative cells to undergo the ADM>ADR>PanIN
sequence (ADR, acinar-to-ductal reprogramming). Hence, TGFb signaling activation enhances the properties of KRASG12D
through its capacity to prime a suitable surrounding for transformation. TAM, tamoxifen. [Pft1a-CreERT-; LSL-TbRICA], CERR;
[Pft1a-CreERT2; LSL-KrasG12D], CERK; [Pft1a-CreERT2; LSL-TbRICA; LSL-KrasG12D], CERKR. TAM, tamoxifen. WT, wild-type.
September 2017 TGFb-signaling Activation in Pancreas 279underlying the initiation of pancreatic cancer is highly
relevant for the development of early detection markers and
new therapies. Indeed, inhibition of TGFb may represent a
therapeutic strategy for impeding ductal reprogramming of
acinar cells to prevent the initiation of PDA in high-risk
patients (hereditary syndrome or chronic pancreatitis).
In conclusion, the present study demonstrates that TGFb
is an ADM inducer, facilitating the development of pancre-
atic neoplastic lesions in a KRASG12D-dependent context.
According to the activated state of KRAS and TGFb signaling,
we propose an integrated and dynamic model for pancreatic
cancer initiation; TGFb activation is not sufﬁcient to induce
PanINs, and KRASG12D is poorly efﬁcient at inducing ADM.
However, when combined, TGFb induces ADM and provides
a propitious setting for KRASG12D-induced transformation
(Figure 11). Deﬁning the molecular mechanisms underlying
the initiation of pancreatic cancer is highly relevant for the
development of early detection markers and of potentially
novel treatments.References
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